Methotrexate is a gold standard among disease modifying antirheumatic drugs and is also extensively used clinically in combination with oncological therapies. Thus, it is not surprising that nuclear medicine found an interest in methotrexate in the search for diagnostic and therapeutic solutions. Numerous folate-related radiopharmaceuticals have been proposed for nuclear medicine purposes; however, methotrexate radioagents represent only a minority. This imbalance results from the fact that methotrexate has significantly weaker affinity for folate receptors than folic acid. Nevertheless, radiolabeled methotrexate agents utilized as a tool for early detection and imaging of inflammation in rheumatoid arthritis patients gave promising results. Similarly, the use of multimodal MTX-release nanosystems may find potential applications in radiosynovectomy and theranostic approaches in folate receptor positive cancers.

中文翻译：

---

基于甲氨蝶呤的放射剂在核医学中的应用前景

甲氨蝶呤是改善疾病的抗风湿药物的金标准，在临床上也广泛用于与肿瘤治疗相结合。因此，在寻找诊断和治疗解决方案时，核医学发现对甲氨蝶呤感兴趣也就不足为奇了。许多与叶酸有关的放射性药物已被提议用于核医学目的；然而，甲氨蝶呤放射剂仅占少数。这种不平衡是由于甲氨蝶呤对叶酸受体的亲和力比叶酸弱得多。然而，放射性标记的甲氨蝶呤药剂用作类风湿性关节炎患者炎症的早期检测和成像工具，取得了有希望的结果。相似地，